Equitable access to costly new drugs
Authors:
Open Access
Abstract
Pricing should consider local value to ensure fair access and health system affordabilityKeywords
This publication has 16 references indexed in Scilit:
- A Systematic Review of Challenges and Opportunities in the Implementation of Managed Entry Agreements for Advanced Therapy Medicinal ProductsClinical Therapeutics, 2024
- Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysisThe Lancet, 2024
- Availability and financing of CAR-T cell therapies: A cross-country comparative analysisHealth Policy, 2024
- Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of BiasPharmacoEconomics, 2024
- Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments requiredHealth Economics, 2024
- Challenges for Economic Evaluations of Advanced Therapy Medicinal Products: A Systematic ReviewValue in Health, 2022
- Empirical Estimates of the Marginal Cost of Health Produced by a Healthcare System: Methodological Considerations from Country-Level EstimatesPharmacoEconomics, 2021
- Country-Level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further ResearchValue in Health, 2016
- Cancer Drugs Fund requires further reformBMJ, 2016
- A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage DecisionsValue in Health, 2016